β‐Catenin‐ RAS interaction serves as a molecular switch for RAS degradation via GSK 3β
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
RAS proteins play critical roles in various cellular processes, including growth and transformation. RAS proteins are subjected to protein stability regulation via the Wnt/β‐catenin pathway, and glycogen synthase kinase 3 beta (GSK3β) is a key player for the phosphorylation‐dependent RAS degradation through proteasomes. GSK3β‐mediated RAS degradation does not occur in cells that express a nondegradable mutant (MT) β‐catenin. Here, we show that β‐catenin directly interacts with RAS at the α‐interface region that contains the GSK3β phosphorylation sites, threonine 144 and threonine 148 residues. Exposure of these sites by prior β‐catenin degradation is required for RAS degradation. The introduction of a peptide that blocks the β‐catenin‐RAS interaction by binding to β‐catenin rescues the GSK3β‐mediated RAS degradation in colorectal cancer (CRC) cells that express MT β‐catenin. The coregulation of β‐catenin and RAS stabilities by the modulation of their interaction provides a mechanism for Wnt/β‐catenin and RAS‐ERK pathway cross‐talk and the synergistic transformation of CRC by both APC and KRAS mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The inconsistency in tumor response between NSCLC and colorectal cancer suggests either that KRAS p.G12C is not the dominant oncogenic driver for colorectal cancer or that other pathways, such as Wnt or EGFR pathways, mediate oncogenic signaling beyond KRAS”
From KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors (2020) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The APC gene in colorectal cancer
Fodde, R. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00040-0 · Cited by 461 · cited 1×
“Adenomatous polyposis coli ( APC ) and KRAS mutations, which occur in 90% [1,2] and 40 – 50% [3,4] of human colorectal cancers (CRCs), respectively, are known to cooperate to synergistically promote CRC [5 – 7].”
Janssen, K., Alberici, P., Fsihi, H., Gaspar, C., Breukel, C., Franken, P., Rosty, C., Abal, M., El Marjou, F., Smits, R., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.011 · Cited by 298 · cited 1×
“The Wnt/ b -catenin and RAS-ERK pathways are major signaling pathways for cellular transformation, and accumulating evidence indicates that both pathways synergistically interact in the tumorigenesis of CRC [5 – 7 ,19].”
Mazhab-Jafari, M. T., Marshall, C. B., Smith, M. J., Gasmi-Seabrook, G. M. C., Stathopulos, P. B., Inagaki, F., Kay, L. E., Neel, B. G., & Ikura, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419895112 · Cited by 220 · cited 3×
“These residues are mostly localized at the a-interface [18], which is mainly orientated parallel to the membrane and is composed of residues T127-K167 (a4, b6, and a5), the N-terminus of b1, and a loop between b2 and b3 (Fig 3C and D, and Appendix Fig S1B).”
Influential
Cited by
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Mutations and mechanisms of WNT pathway tumour suppressors in cancer
Bugter, J. M., Fenderico, N., & Maurice, M. M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00307-z · Cited by 466
Lim, S., Khoo, R., Juang, Y.-C., Gopal, P., Zhang, H., Yeo, C., Peh, K. M., Teo, J., Ng, S., Henry, B., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01337 · Cited by 80
K-Ras prenylation as a potential anticancer target
Baranyi, M., Buday, L., & Hegedűs, B. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09902-w · Cited by 62
Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology
László, L., Kurilla, A., Takács, T., Kudlik, G., Koprivanacz, K., Buday, L., & Vas, V. (2021) · Cells · doi:10.3390/cells10030667 · Cited by 58
“Therefore, one possible therapeutic intervention against mutant KRAS would be to directly target GSK3β to increase its activation to deregulate β-catenin [20].”
Background
Metadata
- Authors
- Lee, S., Jeong, W., Cho, Y., Cha, P., Yoon, J., Ro, E. J., Choi, S., Oh, J., Heo, Y., Kim, H., Min, D. S., Han, G., Lee, W., & Choi, K.
- Venue
- EMBO reports
- Published
- 2018-11-09
- Volume
- 19
- Issue
- 12
- ISSN
- 1469-221X (ISSN-L)
- 1469-3178
- OpenAlex
- W2900422075
- Cited by
- 44
- References
- 3
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: β‐Catenin‐ RAS interaction serves as a molecular switch for RAS degradation via GSK 3β. https://app.cochat.ai/papers/10.15252/embr.201846060
- The paper
- Lee, S., Jeong, W., Cho, Y., Cha, P., Yoon, J., Ro, E. J., Choi, S., Oh, J., Heo, Y., Kim, H., Min, D. S., Han, G., Lee, W., & Choi, K. (2018). β‐Catenin‐ RAS interaction serves as a molecular switch for RAS degradation via GSK 3β. EMBO reports. https://doi.org/10.15252/embr.201846060
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.